E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Anti-TNF induced psoriasiform skin lesions in patients with inflammatory bowel diseases |
anti-TNF therapie veroorzaakte psoriasiforme huidletsels in patiënten met chronische onstekingsziekten van de darm |
|
E.1.1.1 | Medical condition in easily understood language |
Skin lesions induced by biological therapy used to treat patients with inflammatory bowel diseases |
huidletsels veroorzaakt door biologische medicatie die gebruikt wordt in de behandeling van patiënten met chronische onstekingsziekten van de darm |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this prospective, observational study is to indentify transcriptomic and proteomic signatures, which can predict good response to ustekinumab in anti-TNF treated patients with psoriasiform skin lesions |
Het primaire doel van de studie is om gen-en eiwitexpressie profielen te ontdekken die kunnen voorspellen of anti-TNF geïnduceerde psoriasiforme huidletsels goed reageren op een behandeling met ustekinumab |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective will include elucidating the changes that occur in the psoriasiform skin lesions when the patient is switched from anti-TNF therapy to ustekinumab or vedolizumab. This is to better understand the mechanisms that contribute to the development of these psoriasiform skin lesions. |
Het secundaire eindpunt in deze studie is om de veranderingen in kaart te brengen die gebeuren op het niveau van de huid bij IBD patiënten met psoriasiforme huidletsels die een medicatie wissel ondergaan van anti-TNF therapie naar ustekinumab of vedolizumab. Dit is om de mechanismen die aan de ontwikkeling van de huidletsels liggen beter te kunnen begrijpen. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All IBD patients aged 18 to 80-years-old who are currently being treated with anti-TNF therapy and who have developed psoriasiform skin lesions (including psoriasiform eczema, psoriasis guttata, psoriasis inversa and pustulosis) and which are refractory to at least 12 weeks of topical therapy. The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures. |
Alle IBD patiënten tussen 18-80 jaar oud dit op heden behandeld worden met anti-TNF therapie en hieronder psoriasiforme huidletsels (inclusief psoriasisiform eczeem, psoriasis guttata, psoriasis inversa en pustulosa) ontwikkelden dewelke refractair zijn aan minstens 12 weken van topische behandeling. Voorafgaand aan hun inclusie dienen de deelnemers een schriftelijk toestemmingsformulier te ondertekenen. |
|
E.4 | Principal exclusion criteria |
- IBD patients not treated with anti-TNF therapy
- IBD patients with paradoxical skin lesions due to anti-TNF who are not refractory to topical therapy
- Patients who previously received anti-IL12/23 or anti-IL23 therapy or vedolizumab.
- Pregnant IBD patients |
- IBD patiënten niet behandeld met anti-TNF therapie
- IBD patiënten onder anti-TNF therapie die geen psoriasiforme huidletsels ontwikkelen
- IBD patiënten met anti-TNF geïnduceerde psoriasiforme huidletsels die wel reageren op topische behandeling
- zwangere IBD patiënten
- IBD patiënten die ooit al werden behandeld met ustekinumab en/of vedolizumab |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary end point is to identify gene and protein expression profiles that predict good response of anti-TNF induced psoriasiform skin lesions to ustekinumab |
het primaire eindpunt is om gen-en eiwitexpressie profielen te ontdekken die de goede respons van psoriasiforme huidletsels voorspellen op ustekinumab |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
within a year after termination of the study |
binnen het jaar na afsluiten van de studie |
|
E.5.2 | Secondary end point(s) |
The secondary end point is to identify mechanistic changes that occur in the skin when the study participants are switched from anti-TNF therapy to either ustekinumab or vedolizumab (control group). |
Het secundaire eindpunt is het bepalen van mechanistische veranderingen die optreden in de huid van de deelnemers wanneer hun medicatie wordt gewisseld naar ustekinumab of vedolizumab (controle groep) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
within the year after termination of the study |
binnen het jaar na het beëindigen van de studie |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For all patients the trial starts when they are switched to either to vedolizumab or ustekinumab due to the development of psoriasiform
skin lesions and after signing a written informed consent, which shows that their participation is voluntary. For both groups the trial ends 16
weeks after changing treatment. |
de studie begint op het moment dat de patiënt gewisseld wordt van anti-TNF therapie naar ofwel ustekinumab ofwel vedolizumab en
eindigt na 16 weken. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |